OS Therapies Incorporated (OSTX)
XASE:OSTX
Want to see OSTX full AI Analyst Report?
Top Page
OS Therapies Incorporated
(NYSE MKT:OSTX)
Select Model
Select Model
Rating:51Neutral
Price Target:
$2.00
▲(38.89% Upside)
Action:Reiterated
Date:06/02/26
Score is held back primarily by weak financial performance (zero revenue, ongoing losses, and continued cash burn with increased debt). Technicals are supportive with price above key moving averages and a positive MACD, but overbought signals add near-term risk. Corporate events are a modest positive due to EMA rolling review progress and extended funding runway, while valuation is constrained by negative earnings and no dividend.
Positive Factors
Regulatory Progress
A formal EMA rolling review with aligned three-year overall survival endpoints, selection for the EMA Raw Data Pilot and UK ATMP status materially de-risks the regulatory pathway. This durable clarity supports coordinated global Phase 3 planning, reimbursement discussions, and increases the probability of conditional approvals that underpin long-term commercial opportunity.
Negative Factors
Persistent Cash Burn
Consistent negative operating and free cash flow across periods shows the company is not self-financing development. Worsening burn in recent periods increases dependence on external capital, making clinical progress contingent on successful financings and elevating long-term dilution and execution risk if milestones slip or funding gaps appear.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory Progress
A formal EMA rolling review with aligned three-year overall survival endpoints, selection for the EMA Raw Data Pilot and UK ATMP status materially de-risks the regulatory pathway. This durable clarity supports coordinated global Phase 3 planning, reimbursement discussions, and increases the probability of conditional approvals that underpin long-term commercial opportunity.
Read all positive factors
OS Therapies Incorporated (OSTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$75.71M
Dividend YieldN/A
Average Volume (3M)693.17K
Price to Earnings (P/E)―
Beta (1Y)0.13
Revenue GrowthN/A
EPS Growth-63.18%
CountryUS
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.07
Shares Outstanding44,538,105
10 Day Avg. Volume687,415
30 Day Avg. Volume693,174
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-6.72
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap6.88
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.44K
Enterprise Value/Ebitda-15.00
Forecast
1Y Price Target
$9.50Price Target Upside559.72% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.64
Revenue Forecast (FY)$2.67M
OS Therapies Incorporated Business Overview & Revenue Model
Company Description
OS Therapies Incorporated is a clinical-stage biopharmaceutical company dedicated to identifying, advancing, and commercializing therapeutic solutions for osteosarcoma and other solid tumors within the United States. Its pipeline highlights OST-HE...
How the Company Makes Money
null...
OS Therapies Incorporated Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
12
Very Negative
| Breakdown | Mar 2026 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -363.08K | -2.78K | -4.22K | -805.00 | -1.16M |
| EBITDA | -28.39M | -6.83M | -4.34M | -4.45M | -4.84M |
| Net Income | -28.75M | -8.88M | -7.79M | -6.25M | -7.42M |
Balance Sheet | |||||
| Total Assets | 6.84M | 5.54M | 798.08K | 509.11K | 325.89K |
| Cash, Cash Equivalents and Short-Term Investments | 269.83M | 5.53M | 38.98K | 171.48K | 80.79K |
| Total Debt | 0.00 | 0.00 | 14.61M | 10.35M | 7.07M |
| Total Liabilities | 12.94M | 4.73M | 24.81M | 18.07M | 11.78M |
| Stockholders Equity | -6.10M | 811.49K | -24.02M | -17.56M | -11.45M |
Cash Flow | |||||
| Free Cash Flow | -14.24B | -7.28M | -3.01M | -3.79M | -4.41M |
| Operating Cash Flow | -14.24B | -7.28M | -3.01M | -3.79M | -4.40M |
| Investing Cash Flow | -466.42M | 0.00 | 1.15K | 230.88K | 200.47K |
| Financing Cash Flow | 9.44B | 12.78M | 2.87M | 3.65M | 3.05M |
OS Therapies Incorporated Risk Analysis
OS Therapies Incorporated disclosed 63 risk factors in its most recent earnings report. OS Therapies Incorporated reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
OS Therapies Incorporated Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $71.66M | -3.34 | -201.43% | ― | ― | 33.86% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $75.71M | -1.86 | 3214.88% | ― | ― | -63.18% | |
43 Neutral | $31.69M | -1.34 | -218.67% | ― | ― | 48.96% | |
42 Neutral | $61.67M | -1.21 | -318.08% | ― | ― | 20.55% |
* Healthcare Sector Average
OSTX
OS Therapies Incorporated
1.70
-0.20
-10.53%
ATNM
Actinium Pharmaceuticals
1.01
-0.52
-33.99%
ANVS
Annovis Bio
1.78
-1.05
-37.10%
GANX
Gain Therapeutics
1.68
-0.06
-3.45%
OS Therapies Incorporated Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
OS Therapies Gains EMA Rolling Review for OST-HER2
Positive
Apr 30, 2026
On April 30, 2026, OS Therapies announced that the European Medicines Agency has begun a rolling review of its conditional marketing authorization application for OST-HER2 in preventing or delaying recurrence of fully resected pulmonary metastatic...
Business Operations and StrategyPrivate Placements and Financing
OS Therapies bolsters funding to advance OST-HER2 program
Positive
Apr 2, 2026
On March 31, 2026, OS Therapies entered into a securities purchase agreement for a registered direct offering of common stock, pre-funded warrants and common warrants, which closed on April 2, 2026 and delivered approximately $4.7 million in net p...
Business Operations and StrategyRegulatory Filings and Compliance
OS Therapies Files Prospectus Supplement for Share Resale
Neutral
Apr 1, 2026
On March 31, 2026, OS Therapies Incorporated filed a prospectus supplement with the U.S. Securities and Exchange Commission as part of an existing Form S-3 shelf registration that had been declared effective in August 2025. The supplement register...
Business Operations and StrategyPrivate Placements and Financing
OS Therapies Raises $2 Million via Convertible Notes
Positive
Mar 6, 2026
On March 4, 2026, OS Therapies Incorporated raised $2 million in gross proceeds through a private placement of 10% original issue discount unsecured convertible promissory notes with an aggregate principal of $2.2 million and accompanying warrants...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.